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evaluated by microscopic examination. Eosinophilia was deﬁned as
a relative eosinophil count greater than 4% on at least one day
within the ﬁrst 100 days after allo-SCT. Eosinophilia was observed
in 135 patients (57%). The cumulative incidence of grades II to IV
acute GVHD was found to be signiﬁcantly higher in patients
without eosinophilia than in those with eosinophilia (68% vs. 43%;
P  0.001). In 15 of 58 (26%) patients with eosinophilia and 41 of
70 (59%) patients without eosinophilia, acute GVHD was resistant
to standard doses of prednisolone and required salvage therapy (P
 0.022). The cumulative incidence of chronic GVHD was sig-
niﬁcantly higher in patients without eosinophilia than in those with
eosinophilia (73% vs. 56%; P  0.011). The cumulative incidence
of relapse in patients with hematologic malignancies was similar
between patients with and without eosinophilia (33% vs. 27%; P
0.438). On the other hand, the cumulative probability of non-
relapse mortality was 10% in patients with eosinophilia, which was
signiﬁcantly lower than that in patients without eosinophilia (31%;
P  0.001), and the estimated overall survival at 3 years was 67%
in patients with eosinophilia, which was signiﬁcantly higher than
that in patients without eosinophilia (51%; P  0.003). Multivar-
iate analysis identiﬁed age above 40 years, high-risk disease, grade
II to IV acute GVHD, sex disparity between patient and donor,
and the absence of eosinophilia as signiﬁcant factors for reduced
overall survival. These data lead us to conclude that eosinophilia
after allo-SCT may serve as a favorable prognostic marker. How-
ever, further prospective studies including detailed cytokine pro-
ﬁling are essential for an understanding of the pathophysiological
mechanisms involved in posttransplant eosinophilia.
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Chronic graft versus host disease (cGVHD) severely impairs the
clinical outcome and life quality after allogeneic stem cell trans-
plantation (allo-SCT). Its pathophysiology is not fully understood,
and treatment often fails. Macrophage migration inhibitory factor
(MIF) is produced by various cell types including T cells, macro-
phages, epithelial cells and shows a broad range of proinﬂamma-
tory properties. A G to C transition at position -173 of the MIF
gene has been associated with the development of various inﬂam-
matory diseases. Here, we assessed the contribution of the minor C
allele to cGVHD development.
Donor-recipient pairs of 405 patients receiving allo-SCT
(matched unrelated donor (URD): n225; matched related donor
(MRD): n180) at four independent centers and surviving 100
days after SCT were genotyped. Stem cells were derived from bone
marrow (n163) or from peripheral blood (n242) and T cell
depletion (TCD) was performed in 30.7% of cases. Mean follow up
was 888	46 days. The C allele (GC or CC genotype) was present
in 29.2% of recipients and 26.7% of donors. No association was
seen between acute GVHD and the G/C polymorphism of either
the donor or the recipient. Overall, 46.8% of all patients developed
cGVHD: 43.1% of patients with a GG genotype donor and 55.4%
of patients when the donor carried a C allele (p0.04). The
incidence of cGVHD was not altered by the patient
s MIF status
(GG: 45.3% vs. GC/CC: 49.1%; p0.6).
In patients receiving URD SCT, the presence of a donor C allele
resulted in an increase in cGVHD development from 47.2 to
63.9% (p0.03). This effect was not seen in MRD SCT (p0.58).
Since T cells are a major source of MIF, we then tested the effect
of TCD on the role of donor MIF in cGVHD development after
URD SCT. cGVHD incidence was signiﬁcantly increased in pa-
tients receiving non-TCD allo-SCT from GC or CC unrelated
donors compared to recipients of GG donor cells (71.1 vs. 52.9%;
p0.045). When TCD was performed, cGVHD occurence was
not affected, independent whether the donor carried the C allele or
not (52.2 vs. 40.0%; p0.2). The presence of a donor C allele
further led to a signiﬁcant increase in treatment related mortality
(TRM) from 6.4 to 28.6% when no TCD was performed
(p0.002), whereas TRM after TCD in both groups ranged be-
tween 31.0 and 32.7%.
Collectively, our data demonstrate a distinct role for donor T cell
derived MIF in the development of cGVHD, which may allow
MIF as a new immunotherapeutic target in future.
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Extracorporeal phototherapy (ECP) is an emerging therapy for
clinical graft-versus-host disease (GVHD) that exposes a patient’s
peripheral white blood cells (WBCs) to photo-activatable 8-methoxy-
psoralen (8-MOP) and UVA light before re-infusing them. We have
developed a novel murine model that closely mirrors ECP treatment
of clinical GVHD to investigate its mechanism of action. C3H.SW
mice were conditioned with 11Gy total body irradiation and injected
with 5.0106 bone marrow and 0.5106 puriﬁed T cells from either
syngeneic (C3H.SW) or allogeneic (B6-Ly5.2) donors. In order to
model ECP as a treatment strategy rather than as prevention, animals
were not treated until GVHDwas clinically evident 7 days after BMT
and then received 4 weekly infusions with 30.0106 8-MOPUVA
treated splenocytes from similarly transplanted mice. Control mice
were infused with untreated splenocytes, and did not show any dif-
ferences from mice treated with L-15 (data not shown). Infusion of
8-MOPUVA-treated splenocytes into allo-BMT recipients resulted
in signiﬁcantly better day 56 survival (74% vs 42%, p0.0007),
reduced GVHD clinical scores (2.9 vs 5.9, p0.004) and GVHD
histopathology in liver (7.3 vs 13.4), gut (11.4 vs 18.4) and skin (0.6 vs
1.2; all organs p0.03) compared to mice infused with untreated
splenocytes. ECP treated allo-BMT recipients also had signiﬁcantly
better immune reconstitution (p0.01) on day 56, with both total
thymocytes and distribution of thymocyte compartments indistin-
guishable from syngeneic controls. In vitro studies showed that98%
of cells were Annexin within 24h of ECP treatment and experiments
using Ly5 congenic donors demonstrated that ECP treated cells are
undetectable in the thymus and spleen following injection. Because
apoptotic cells are known to induce tolerance in several systems, we
hypothesized that ECP increased the number of T regulatory cells
(Treg). The number of CD4CD25Foxp3 Treg in ECP-treated
allo-BMT recipients was signiﬁcantly increased compared to mice
infused with untreated splenocytes in the thymus (2.5 vs 1.0104,
p0.02) and the spleen (1.8 vs 1.1105, p0.008). We conclude that
4 weekly infusions of ECP treated cells beginning after GVHD
induction signiﬁcantly decreases acute GVHD by all clinical, patho-
logical and cellular parameters and is associated with increased num-
bers of Tregs.
SYN ALLO ALLO
/- ECP No ECP Spl ECP Spl p-value*
Number 15 19 34
Day 56 Analysis:
Survival 100% 42% 74% 0.0007
GVHD Clinical Score 1.10.4 5.90.3 2.90.4 0.004
Pathology
Liver 2.10.9 13.45.5 7.32.5 0.0001
Intestine 7.42.8 18.45.7 11.43.1 0.0003
Skin 0 1.20.7 0.60.6 0.03
Thymic reconstitution
Thymocytes (x106) 12.49.9 2.22.1 7.77.2 0.01
Thymic Treg (x104) 5.12.6 1.00.6 2.51.4 0.02
Spleen Treg (x105) 6.22.9 1.10.4 1.80.1 0.008
* 95% conﬁdence level, AlloECP Spl vs AlloNo ECP Spl
Oral Presentations12
